NBIX - Neurocrine Biosciences Inc.

NBIX Stock Chart

NBIX Profile

Neurocrine Biosciences, Inc. is dedicated to discovering, devvelloping, and marketing pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio features treatments for conditions such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside various clinical programs targeting different therapeutic areas. Their lead product, INGREZZA, is a VMAT2 inhibitor designed to treat tardive dyskinesia. Additionally, their commercial offerings include ONGENTYS, a catechol-O-methyltransferase inhibitor used in conjunction with levodopa/DOPA decarboxylase inhibitors for Parkinson's disease patients; ORILISSA, which manages moderate to severe endometriosis pain in women; and ORIAHNN, an oral medication for managing heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

The company has several promising product candidates in clinical development. These include NBI-921352, aimed at treating pediatric patients and adult focal epilepsy indications; and NBI-827104, developed for rare pediatric epilepsy and essential tremor. Other products in their pipeline are NBI-1065845 for major depressive disorder, NBI-1065846 for treating anhedonia in major depressive disorder, and NBI-118568 for the treatment of schizophrenia. These clinical developments demonstrate Neurocrine's commitment to addressing unmet medical needs across a spectrum of neurological and psychiatric conditions.

Neurocrine Biosciences, Inc. has established various license and collaboration agreements with notable entities such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL – Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Founded in 1992 and headquartered in San Diego, California, Neurocrine continues to innovate and expand its impact in the pharmaceutical industry.

NBIX Revenue Chart

NBIX Earnings

Analyst Ratings